8-K: Zynex Reports Disappointing First Quarter 2025 Results Amidst Tricare Payment Suspension

Zynex reports a significant drop in revenue and a net loss for Q1 2025, impacted by a temporary payment suspension from Tricare and reduced sales force.

Summary

• Zynex reported its Q1 2025 financial results, showing a decrease in net revenue to $26.6 million compared to $46.5 million in the same quarter last year.
• The company experienced a net loss of ($10.4) million, or ($0.33) per share, a stark contrast to the net income of $10,000 in Q1 2024.
• Adjusted EBITDA also declined significantly to ($11.8) million from $1.7 million in the prior year quarter.
• The company's gross profit margin decreased to 69% from 80% due to the Tricare payment suspension and continued support for Tricare patients.
• Zynex expects Q2 2025 net revenue to be at least $27 million and loss per share to be ($0.20) or better.
• The company reduced its staff by approximately 15% in Q1, expecting annual savings of around $35 million.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the significant decline in revenue, net loss, and the uncertainty surrounding the Tricare payment suspension. While management expresses optimism, the financial results indicate substantial challenges.

Positives

• The company is focusing on sales rep productivity, which showed strong performance despite a 39% reduction in sales force headcount.
• Expense reduction efforts, including a 15% staff decrease, are expected to result in $35 million in annual savings.
• Zynex expects to complete its FDA submission for the NiCO laser pulse oximeter, potentially driving new revenue streams.
• The company continues to support existing and new Tricare patients despite the payment suspension.
• Zynex expects quarterly revenues to increase throughout the year with the usual seasonality typically experienced.

Negatives

• Net revenue decreased significantly to $26.6 million from $46.5 million year-over-year.
• The company reported a net loss of ($10.4) million, compared to a net income of $10,000 in the prior year quarter.
• Adjusted EBITDA declined to ($11.8) million from $1.7 million in the same period last year.
• Gross profit margin decreased to 69% from 80%.
• Total orders decreased 3% year-over-year.
• Cash flows from operations for the three months ended March 31, 2025, was ($10.5) million.

Risks

• The temporary suspension of payments from Tricare, Zynex's largest insurance customer, significantly impacted revenue and profitability.
• The company's dependence on reimbursement from health insurance companies poses a risk to its financial performance.
• The acceptance of new and existing products by doctors and hospitals is crucial for revenue generation.
• Larger competitors with greater financial resources could pose a threat.
• The company faces the risk of needing to keep pace with technological changes.
• Market conditions and economic factors, such as interest rate fluctuations, could impact the company's performance.

Future Outlook

The Company expects Q2 2025 net revenue of at least $27 million and loss per share to be ($0.20) or better, with quarterly revenues expected to increase throughout the year with the usual seasonality typically experienced.

Management Comments

• In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products.
• Total orders decreased 3% year-over-year, but our sales force headcount was approximately 39% less as we continue to focus on sales rep productivity, so we were encouraged by the strong performance of the current sales reps.
• We were notified of a temporary suspension of payments from our largest insurance customer, Tricare.
• We made the difficult decision to decrease our overall staff by approximately 15% in the first quarter, which along with other expense reduction efforts should result in savings of approximately $35 million annually.
• We expect to complete our FDA submission for our NiCO laser pulse oximeter in the next couple of weeks, which we believe can be a significant driver of new customers, revenue streams and will diversify our product offering.
• Overall, we remain optimistic about the growth opportunities both in pain management and patient monitoring.

Industry Context

The medical device industry is highly competitive, with companies constantly innovating and seeking regulatory approvals for new products. Zynex's focus on pain management and patient monitoring aligns with growing healthcare needs, but the company faces challenges related to reimbursement and competition.

Comparison to Industry Standards

• Comparing Zynex's performance to similar medical device companies like Nevro Corp or Stimwave, which also focus on pain management, reveals that Zynex's revenue decline and net loss are significant deviations from industry growth trends.
• Companies like Masimo, which specialize in patient monitoring technology, generally maintain higher gross profit margins, indicating Zynex's challenges with cost management and reimbursement issues.
• The temporary suspension of payments from Tricare is a unique challenge for Zynex, as other companies in the industry typically have more diversified revenue streams.

Stakeholder Impact

• Shareholders are negatively impacted by the decreased revenue, net loss, and decline in Adjusted EBITDA.
• Employees were impacted by the 15% staff reduction.
• Customers may experience uncertainty due to the Tricare payment suspension.
• Suppliers may be affected by the company's cost reduction efforts.
• Creditors may be concerned about the company's financial performance and ability to meet its obligations.

Next Steps

• Zynex expects a response from Tricare regarding the payment suspension appeal in June.
• The company anticipates completing its FDA submission for the NiCO laser pulse oximeter.
• Zynex will continue to monitor expenses and adjust as necessary.
• The company will hold a conference call and webcast to discuss the Q1 2025 financial results.

Key Dates

Keywords

Zynex, financial results, Q1 2025, net revenue, net loss, EBITDA, Tricare, medical devices, pain management, patient monitoring